804.35
-0.33%
Close of 9 Nov 2026, in INR
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Natco Pharma
Its shares trade on NSE under the ticker NATCOPHARM.NS. It has been listed since 23 January 1995. In the fiscal year to 31 March 2026, it reported revenue of ₹40.78bn and net income of ₹14.19bn. At that date it held total assets of ₹110.74bn and shareholders' equity of ₹92.21bn.
NATCO Pharma Ltd. engages in the business of pharmaceuticals with research, manufacturing and marketing of finished dosage formulations and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana. The firm is engaged in the development, manufacture and commercialization of complex pharmaceuticals catering to niche therapeutic areas. The firm deals in the production of finished dosage formulations (FDF), which it sells in India, the United States and the Rest of the World, as well as active pharmaceutical ingredients (APIs). Its capabilities include multi-step synthesis, semi-synthetic fusion technologies, production of high-potency APIs and peptides. The firm operates through two segments: pharmaceuticals and agrochemicals. The pharmaceuticals segment, the Company drives its sales through FDFs and APIs. The agrochemicals segment is focused on niche products, including pest management.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Pharmaceuticals
- Listed since
- 23 Jan 1995
- Employees
- 4,760
- Website
- natcopharma.co.in ↗
Leadership
Pay as last reported
- Shri. Venkaiah NannapaneniChairman of the Board, Managing Director, Executive Director, since 2024₹100.8m
- Sri. Rajeev NannapaneniChief Executive Officer, Vice Chairman of the Board, Executive Director, since 2005₹98.7m
- Mr. S. V. V. N. Appa RaoChief Financial Officer₹2.6m
- Dr. Linga Rao DonthineniPresident - Technical Affairs, Executive Director, since 2015₹33.7m
- Sri. Potluri PrasadExecutive Vice President - Corporate Engineering Services, Executive Director, since 2014₹20.2m
- Mr. Rajesh ChebiyamExecutive Vice President - Crop Health Sciences₹6.0m
- Dr. Ramesh DandalaExecutive Vice President - Technology Transfer, Intellectual Property Rights and Regulatory Affairs (API)₹8.6m
- Dr. M. Pulla ReddyExecutive Vice President - R&D₹14.3m
- Mr. Lakshminarayana AreSenior Vice President - HR & OD, since 2023
- Mr. Imtiyaz BasadeSenior Vice President - RAD
- Mr. Srinivas C. H.Senior Vice President - Demand and Supply Planning, since 2023
- Mr. Bhimrao JadhavSenior Vice President - Operations (Formulations)
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 75
- Environment
- 90
- Social
- 99
- Governance
- 35
- Direct emissions (scope 1)
- 28,403.25 t
- Energy emissions (scope 2)
- 41,763.62 t
- Women in the workforce
- 8.839%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Strong presence in the pharmaceutical industry.
- Diversified product portfolio covering various therapeutic segments.
- Well-established manufacturing capabilities and quality control systems.
- Effective distribution network ensuring wide market reach.
Weaknesses
- Dependence on key customers for revenue generation.
- Limited global footprint compared to some competitors.
- Relatively lower brand recognition in certain international markets.
Opportunities
- Rising demand for generic medicines due to increasing healthcare costs.
- Growing focus on research and development for new drug discoveries.
- Expansion into emerging markets with untapped potential.
- Strategic partnerships and collaborations to enhance product offerings.
Threats
- Intense competition from both domestic and international pharmaceutical firms.
- Stringent government regulations and legal challenges in intellectual property rights.
- Economic downturns impacting consumer spending on healthcare.
- Possible shifts in healthcare policies affecting pricing and reimbursement.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.